Pharma Mar, S.a.

Centro Nacional De Investigaciones Cardiovasculares Carlos III (f.s.p.)

Parma Mar, S.a.

Centro Nacional De Investigaciones Cardiovasculares Carlos III

Francisco Sánchez Madrid

Andrés Francesch Solloso

María Garranzo García-Ibarrola

Juan Manuel Zapata Hernández

Alicia García Arroyo

Carmen Cuevas Marchante

Juan Manuel Domínguez Correa

Maria Angeles Ursa Pecharroman

María José Munoz Alonso

María Pilar Martín Fernández

Raquel Sánchez Díaz

Adela Matesanz Marín

Luis Jesús Jiménez Borreguero

Cármen Cuevas Marchante

Juan Manuel Dominguez Correa

Maria Ángeles Ursa Pecharromán

Maria Jose Munoz Alonso

Luis Jesús JIMÉNEZ Borreguero

Maria ÁNgeles Ursa PECHARROMÁN

Drug conjugates of formula [D-(X)-(AA)-(L)-]-Ab wherein:

Antibody drug conjugates

The present invention provides an in vitro method for obtaining data useful for diagnosing a cardiomyopathy in a human subject, wherein the method comprises using, as an indicator, the expression levels, obtained from a biological sample isolated from the human subject, preferably a plasma sample, of one or more of the following miRNAs miR-721 and/or miR-155); and obtaining a result of the method by comparing the expression levels of said one or more miRNAs with a reference value or with the expression levels of a control, indicator of the absence of cardiomyopathy.

Method for diagnosing cardiomyopathies

Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R, Rand Ris H, OR, OCOR, OCO&#x2014;OR, alkyl, alkenyl, alkynyl, etc.; R' is, COR, COOR, CONRR, etc; each of Rto Rand Ris alkyl, alkenyl or alkynyl; Ris H, COR, COOR, alkyl, alkenyl or alkynyl, or Rand R+N+C atoms to which they are attached may form a heterocyclic group; each of Rand Ris H, COR, COOR, alkyl, alkenyl or alkynyl; each Rand Ris H, alkyl, alkenyl, alkynyl, etc.; each dotted line represents an optional additional bond; X is an extending group; AA is an amino acid unit; L is a linker group; w is 0 to 12; b is 0 or 1; A bis a moiety comprising at least one antigen binding site, and n is the ratio of the group [D-(X)-(AA)-(L)-] to the moiety comprising at least one antigen binding site and is in the range from 1 to 20, are useful in the treatment of cancer. 

Growing community of inventors

Madrid, Spain

Francisco Sánchez Madrid